Clinical trial

Determining Optimal Dose of Corticosteroids in COPD Exacerbations: A Pilot Study

Name
0220120019
Description
COPD (chronic obstructive pulmonary disease) is a long-lasting lung disease usually caused by long-term smoking. COPD can get worse, making people sick enough to need hospitalization. Corticosteroids are very effective and are almost always used, but nobody knows the right dose. High doses may work better but could cause more side effects than low doses. Typical treatment lengths last at least one week. This study will be comparing two common regimens: either 40mg of corticosteroids daily (low dose), or 80mg of corticosteroids daily (high dose). It is unknown which regimen works better..
Trial arms
Trial start
2012-05-03
Estimated PCD
2020-03-15
Trial end
2020-03-15
Status
Terminated
Phase
Early phase I
Treatment
Low Dose Corticosteroids
Arms:
Low Dose Corticosteroids
Other names:
prednisone, methylprednisolone, Solumedrol
High Dose Corticosteroids
Arms:
High Dose Corticosteroids
Other names:
prednisone, methylprednisolone, Solumedrol
Size
89
Primary endpoint
Treatment Failure
30 days
Eligibility criteria
Inclusion Criteria: i. Patients with a diagnosis of COPD, emphysema, or chronic bronchitis ii. Age ≥ 40 years-old iii. Smoking history ≥ 10 pack-years iv. Presentation to the emergency room with increased dyspnea, increased sputum, or increased cough v. Admission to the hospital Exclusion Criteria: i. Alternative diagnosis for cause of dyspnea, increased sputum or cough ii. Patients who requires intubation at time of recruitment iii. Patients who are unable to give consent iv. Patients who are pregnant or could be pregnant or are currently breast-feeding v. Women of child-bearing age who cannot use methods of contraception as described in the consent, including condoms, female condoms, cervical caps, diaphragms, and intra uterine devices. vi. Patients who were previously entered into the trial and are re-admitted to the hospital with a new COPD exacerbation.
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE4'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 89, 'type': 'ACTUAL'}}
Updated at
2024-04-10

1 organization

2 products

1 indication